Skip to main content
DRS $45.53 +1.81%
DRS logo

DRS · Leonardo DRS, Inc.

Track DRS — free
$45.53 +0.81 (+1.81%) At close · Aug 14
Market Cap
$12.15B
Shares
266.89M
All earnings calls

Earnings call · FY2025 Q4

Leonardo DRS, Inc. Q4 FY2025 Earnings Call

Leonardo DRS, Inc. Q4 FY2025 Earnings Call

Concluded Feb 24, 2026 Audio replay
Feb 24, 2026 47:46 55 turns
Period
FY2025 Q4
Runtime
47:46
Sources
4 artifacts

Executive readout · one minute

What matters this quarter

Leonardo DRS delivered record bookings and 13% full-year organic revenue growth to $3.6B with a 1.2x book-to-bill and $8.7B backlog, while adjusted EBITDA margins were flat at 12.4% as elevated R&D and germanium supply constraints weighed on profitability, and the company initiated 2026 guidance.

R&D and capital investment 22 Space and SDA Tranche 3 win 17 European market and Leonardo partnership 13 Legacy program loss and license agreement 10 Record bookings and revenue growth 9 Germanium and supply chain 7

Management tone

Confident

Net tone +72 · low hedging

Grounding quotes
  • “We delivered another year of record bookings, and that was accompanied by robust organic revenue growth of 13% marking back-to-back years of double-digit growth.”
  • “These indicators support our confidence in sustained demand.”
  • “On balance, 2025 was a strong year, and we're focused on building on that momentum in 2026 and beyond.”
  • “While price volatility may persist in the near term, we will reprice contract renewals on a rolling basis to reflect market conditions and incorporate contractual protections against future potential shocks.”

Forward guidance

5 guided metrics

Management's latest ranges and targets are included below.

Research coverage

4 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $1.06B +8.1% YoY
Gross margin · derived Q4 25.4% +1.4 pp YoY
Net income · derived Q4 $102.00M +14.6% YoY

Research materials

Open the source you need; every reader stays inside this workspace.

Key takeaways

What improved, and what deserves a closer read.

Constructive signals

  • Full-year revenue grew 13% organically to $3.6B with back-to-back years of double-digit growth
  • Full-year bookings of $4.2B produced a 1.2x book-to-bill, marking the fourth consecutive year at 1.2x or better
  • Year-end backlog rose 3% to $8.7B, providing visibility into 2026 growth
  • Full-year free cash flow grew 19% despite materially higher CapEx
  • Net earnings increased 31% to $278M and adjusted diluted EPS rose 24% to $1.15
  • Secured a landmark position on the SDA Tracking Layer Tranche 3 space program

Risks & pressure points

  • Full-year adjusted EBITDA margin was flat at 12.4% as elevated R&D and germanium supply constraints pressured profitability
  • Germanium raw material shortages created supply chain complexity, with price volatility expected to persist in the near term
  • Recognized a non-anticipated loss on a legacy foreign ground surveillance program concluded via MOU
  • Prior 2026 target of 14% EBITDA margin is no longer achievable, with new multiyear targets deferred until Q1 2027
  • Adjusted EBITDA margin declined 20 bps quarter-over-quarter to 14.9% in Q4

Key moments

Jump directly to management's words in the synchronized transcript.

“We delivered another year of record bookings, and that was accompanied by robust organic revenue growth of 13% marking back-to-back years of double-digit growth. Year-end backlog stood at $8.7 billion, providing clear visibility into 2026 growth.” John Baylouny, CEO

Forward guidance

From the 8-K filed Feb 24, 2026.

Metric Guided
Revenue table
2026 Guidance
$3.85B – $3.95B
Adjusted EBITDA table
2026 Guidance
$505M – $525M
Tax Rate table
2026 Guidance
18.5%
Adjusted Diluted EPS table
2026 Guidance
$1.20 – $1.26

Guidance from the call

Stated verbally and extracted from the transcript.

Metric Guided
Capital expenditures as a percentage of revenue
2026
up to 5%

Quarter detail

How the reported period landed and where the business moved.

Capital returned

Buybacks · derived
$11.00M
Dividend / share
$0.09
Full-screen source Call document